Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2026 09:15 ET | Source: Biofrontera Inc.

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”),...
February 24, 2026 08:45 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine...
February 24, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
February 23, 2026 08:40 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging...
February 18, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

We are pleased with advancements made with our R&D programs and... our lead asset PRP which we are preparing for our world-first, Phase 1b, clinical study
February 17, 2026 09:15 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and...
February 17, 2026 09:15 ET | Source: GRI Bio, Inc.

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
February 05, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
February 05, 2026 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or...
January 29, 2026 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen...